The objective was to compare clinical protection [evaluated through health scoring, endoscopy score of the upper respiratory tract (URT-ES), leukocyte count, viremia, and virus shedding in nasal secretions] following Bovine viral diarrhea virus 2 (BVDV2) and Bovine herpes virus 1 (BHV1) challenge among calves submitted to modified-live virus (MLV) booster vaccination (either intranasal or subcutaneous) concurrent with injectable trace minerals (ITM) or saline. Forty-eight dairy calves received an MLV intranasal (IN) vaccine containing BHV1, BRSV, and BPIV and subcutaneous (SC) ITM (Se, Cu, Zn & Mn; ITM, n = 24) or saline (SAL, n = 24). Ten weeks later, calves received a second dose of ITM, or saline, according to previous groups and were randomly assigned to receive the same IN vaccine [ITM-IN (n = 12), SAL-IN (n = 12)] or a SC MLV vaccine containing BHV1, BRSV, BPI3V, BVDV1 & 2 [ITM-SC (n = 12), SAL-SC (n = 12)]. Additionally, 12 calves did not receive vaccine or treatment and served as a control group (UNVAC, n = 12). Forty-nine days after booster, calves were challenged with BVDV2; and seven days later with BHV1. Health scores indicated disease in UNVAC on days 6, 10 and 12 compared to the vaccinated groups. Unvaccinated calves had the highest URT-ES after BHV1 challenge. Calves that received SC booster had lower URT-ES after BHV1 challenge than UNVAC calves. Calves in ITM-IN had significantly lower URT-ES after BHV1 infection than SAL-IN and UNVAC calves. In conclusion, IN or SC MLV vaccination was similarly effective in protecting calves from BVDV2 + BHV1 challenges (reducing clinical and endoscopy scores, preventing leukopenia, and viremia), compared to unvaccinated calves. Endoscopic evaluation of the URT allowed visualization of the inflammation and damage at multiple depths in the URT caused by a serial BVDV2 + BHV1 challenge. Calves that received SC vaccination had significantly lower URT-ES after BHV1 challenge than the UNVAC calves. Administration of ITM concurrent with IN vaccination was associated with reduced URT inflammation after BVDV2 + BHV1 challenge.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rvsc.2022.09.026DOI Listing

Publication Analysis

Top Keywords

bhv1 challenge
16
calves received
16
urt-es bhv1
16
calves
15
challenge calves
12
lower urt-es
12
unvac calves
12
upper respiratory
8
respiratory tract
8
dairy calves
8

Similar Publications

Article Synopsis
  • The study aimed to assess how different routes of vaccine administration and the use of injectable trace minerals (ITM) affect immune responses in dairy calves infected with BVDV2 and BHV1.
  • A total of 60 calves were vaccinated and monitored for immune cell counts, revealing that unvaccinated calves showed significantly lower leukocyte levels compared to vaccinated ones.
  • Results indicated that calves receiving subcutaneous vaccinations had better immune response, particularly in CD4 T cells, and those in the ITM-IN group had the highest CD8 T cell counts, highlighting the importance of both the vaccination method and ITM usage in immune system effectiveness.
View Article and Find Full Text PDF

An injectable subunit vaccine containing Elongation Factor Tu and Heat Shock Protein 70 partially protects American bison from infection.

Front Vet Sci

June 2024

Ruminant Diseases and Immunology Research Unit, National Animal Disease Center, Agricultural Research Service, United States Department of Agriculture, Ames, IA, United States.

() is the etiologic agent of high mortality epizootics of chronic respiratory disease in American bison (). Despite the severity of the disease, no efficacious commercial vaccines have been licensed for the prevention of infection in bison. Elongation factor thermal unstable (EFTu) and Heat Shock Protein 70 (Hsp70, ) are highly conserved, constitutively expressed proteins that have previously been shown to provide protection against infection in cattle.

View Article and Find Full Text PDF

Objective: Compare immune responses induced by 2 commercial intranasal (IN) modified-live viral (MLV) vaccines given individually or coadministered and evaluate prevention of infection and lung pathology following bovine herpesvirus-1 (BHV-1) challenge.

Animals: 36 male Holstein calves (ages, 5 to 12 days).

Methods: In a randomized complete block design, each calf received an IN injection of either vaccine diluent (Placebo), an MLV vaccine containing bovine herpesvirus-1 (BHV-1; N3), bovine coronavirus vaccine (BC), or both N3 and BC (BC + N3) with a booster 4 weeks later.

View Article and Find Full Text PDF

Objective: To determine the efficacy of primary or booster intranasal vaccination of beef steers on clinical protection and pathogen detection following simultaneous challenge with bovine respiratory syncytial virus and bovine herpes virus 1.

Methods: 30 beef steers were randomly allocated to 3 different treatment groups starting at 2 months of age. Group A (n = 10) was administered a single dose of a parenteral modified-live vaccine and was moved to a separate pasture.

View Article and Find Full Text PDF

Mannheimia haemolytica increases Mycoplasma bovis disease in a bovine experimental model of BRD.

Vet Microbiol

August 2023

Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, 120 Veterinary Rd, Saskatoon S7N 5E3, SK, Canada. Electronic address:

Amongst the bacterial pathogens associated with the bovine respiratory disease syndrome (BRD) in cattle are Mannheimia haemolytica and Mycoplasma bovis. The interaction between these two pathogens has not been investigated before; thus, there are gaps in the knowledge of why and how a previous infection with M. haemolytica allows the development of M.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!